NCT01650584

Brief Summary

To assess the comfort preference of ISTA Tears vs Systane in patients with dry eye disease (DED)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2012

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2012

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 24, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 26, 2012

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2013

Completed
7.8 years until next milestone

Results Posted

Study results publicly available

October 6, 2020

Completed
Last Updated

October 8, 2024

Status Verified

September 1, 2020

Enrollment Period

6 months

First QC Date

July 24, 2012

Results QC Date

August 24, 2020

Last Update Submit

October 1, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage of Participants With Preference for One of the Treatments

    There were 35 participants who applied ISTA Tears to the right eye and Systane to the left eye (70 eyes total). Participants were asked to indicate which treatment they preferred, or if they preferred neither.

    30 days

Study Arms (2)

ISTA Tears

EXPERIMENTAL

Sterile ophthalmic solution

Drug: ISTA Tears

Systane

ACTIVE COMPARATOR

Sterile ophthalmic solution

Drug: Systane

Interventions

sterile ophthalmic solution

ISTA Tears

Sterile ophthalmic solution

Systane

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • OSDI \>12

You may not qualify if:

  • Presence of any active ocular disease other than dry eye

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ISTA Pharmaceuticals, Inc.

Irvine, California, 92618, United States

Location

MeSH Terms

Conditions

Dry Eye Syndromes

Condition Hierarchy (Ancestors)

Lacrimal Apparatus DiseasesEye Diseases

Results Point of Contact

Title
Study Director
Organization
Bausch Health

Study Officials

  • Tim McNamara, PharmD

    ISTA Pharmaceuticals, Inc.

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 24, 2012

First Posted

July 26, 2012

Study Start

June 1, 2012

Primary Completion

December 1, 2012

Study Completion

January 1, 2013

Last Updated

October 8, 2024

Results First Posted

October 6, 2020

Record last verified: 2020-09

Locations